Artemisinin CAS#63968-64-9
Highly effective and fast-acting against malaria, with global efficacy over 90% in artemisinin-based combination therapies (ACT).
Strong and rapid killing effect on the erythrocytic stage of Plasmodium, quickly controlling clinical attacks and symptoms.
Broad-spectrum activity against multiple diseases, including chicken coccidiosis, swine eperythrozoonosis, toxoplasmosis, and various forms of malaria (vivax, malignant, cerebral, and chloroquine-resistant).
Low toxicity and additional therapeutic benefits, such as heat-clearing, summer-heat-relieving, and protozoon-killing properties.
Product Description of Artemisinin CAS#63968-64-9
Artemisinin is recognized as one of the most effective drugs for the treatment of malaria. It is a sesquiterpene lactone compound containing a peroxide bridge, extracted from the traditional Chinese medicinal herb Artemisia annua.
The product is characterized by high efficacy, rapid onset, protozoacidal activity, and low toxicity, while also offering traditional therapeutic properties such as heat-clearing and summer-heat-relieving effects.
At present, artemisinin-based combination therapy (ACT) has achieved an efficacy rate of over 90% worldwide in the treatment of malaria and has been widely adopted in clinical use across many countries. Artemisinin demonstrates a strong and rapid killing effect on the erythrocytic stage of Plasmodium, enabling quick control of clinical symptoms and acute attacks.
In addition, it shows remarkable efficacy in a broad range of applications, including chicken coccidiosis, swine eperythrozoonosis, toxoplasmosis, yin deficiency fever, damp-heat jaundice, vivax malaria, malignant malaria, cerebral malaria, and chloroquine-resistant malaria.
Parameters
| Melting point | 156-157 °C (lit.) |
| alpha | 76 º (c=0.5,MeOH) |
| Boiling point | 344.94°C (rough estimate) |
| density | 1.0984 (rough estimate) |
| refractive index | 75 ° (C=0.5, MeOH) |
| storage temp. | -20°C |
| solubility | Soluble to 100mM in DMSO and to 75mM in ethanol |
| form | White to off-white crystalline solid. |
| color | Needles |
| optical activity | [α]20/D +76°, c = 0.5 in methanol |
| Merck | 14817 |
| Stability: | Stable. Combustible. Incompatible with strong oxidizing agents, acids, acid chlorides, acid anhydrides. May absorb, and react with, carbon dioxide from the air. |
| InChI | InChI=1S/C15H22O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-11,13H,4-7H2,1-3H3/t8-,9-,10+,11+,13-,14-,15-/m1/s1 |
| InChIKey | BLUAFEHZUWYNDE-NNWCWBAJSA-N |
| SMILES | O1[C@]23[C@@]4([H])O[C@@](C)(CC[C@@]2([H])[C@H](C)CC[C@@]3([H])[C@@H](C)C(=O)O4)O1 |
| LogP | 2.9 |
Safety Information
| Safety Statements | 22-24/25 |
| WGK Germany | 2 |
| RTECS | KD4170000 |
| HS Code | 29322985 |
| Toxicity | LD50 in mice (mg/kg): 5105 orally; 2800 i.m.; 1558 i.p. (Koch); LD50 in mice, rats (mg/kg): 4228, 5576 orally; 3840, 2571 i.m. (China Cooperative Research Group on Qinghaosu) |
Product Application of Artemisinin CAS#63968-64-9
Artemisinin, derived from Artemisia annua, is widely used as an antimalarial agent. Clinical applications have demonstrated that artemisinin and its derivatives are highly effective against Plasmodium infections and severe falciparum malaria, particularly Artemether, which shows a stronger killing effect on the asexual stages of Plasmodium than other artemisinin-based drugs.
It offers the advantages of high efficacy, rapid onset, low toxicity, and no cross-resistance with chloroquine. In addition to routine treatment, it is also suitable for emergency antimalarial therapy. The product is applicable to multiple forms of malaria, including falciparum malaria, vivax malaria, chloroquine-resistant malaria, cerebral malaria, and severe high-risk cases.
Among its derivatives, dihydroartemisinin and its tablet formulations are particularly noteworthy. Their antimalarial activity is reported to be 10 times higher than that of artemisinin, with a recurrence rate of only 1.95%. As a result, it was recognized as one of the Top Ten Scientific and Technological Achievements in China’s Chemical Industry in 1992.
Beyond malaria treatment, artemisinin and its derivatives also show promising therapeutic potential in other diseases. Animal studies have shown:
100% deworming rate in the treatment of mouse Clonorchis sinensis
33.8–99.3% deworming efficacy against animal schistosomiasis
In addition, the overall effective rate in treating discoid lupus erythematosus reaches 90%, while its efficacy in the treatment of dengue fever has been shown to be significantly superior to certain conventional western medicines.
Immunological studies have further demonstrated that artemisinin can significantly increase lymphocyte transformation rates and enhance antibody-mediated immune function. No toxic effects on the heart, liver, or kidneys have been identified, and no obvious side effects have been observed in clinical practice.
